Medesis Pharma has received a grant of 300,000 euros from AFM-Téléthon to fund the first phases of preclinical development of its RNA interference treatment for Huntington’s disease, the company announced.
Huntington’s disease is a rare, hereditary neurodegenerative disease that causes motor, cognitive and psychiatric dysfunction. Affected individuals eventually become bedridden and develop severe intellectual deterioration, the company said in a press release. Current treatments are symptomatic.
The fatal disease is caused by mutations within an increased number of